full of microplastics and writing about psychedelics at psychedelicalpha.com ( @psychedelicalpha.bsky.social )
josh hardman
Loading...
What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care
psychedelicalpha.com/news/what-ap...
⚖️🇺🇲 January 2026 Psychedelic Bill Round-Up: 75 Bills in Flight... and Counting
Legislative sessions across the U.S. have got off to a lively start this year, with dozens of new psychedelics-related bills introduced.
psychedelicalpha.com/news/january...
Psychedelic Alpha turns 6 this month.
To mark the occasion, we have completely rebuilt the website: new design, faster performance, better navigation across Bulletins, data products, interviews, and more.
Explore the new site: psychedelicalpha.com
Someone has written a 'Request for Congressional Oversight' of certain psychedelics orgs
Psymposia and Psychedelic Alpha = only sources cited. PSA: Psychedelic Alpha is not involved.
In fact, the author harassed me last spring and threatened to contact Interpol(!)
Bizarre.
Introducing the Pα+ Psychedelic Bill Tracker
Monitor the status of every psychedelics-related bill working its way through both state and federal legislatures in the U.S.
Available now: psychedelicalpha.com/data/psyched...
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.
psychedelicalpha.com/news/after-t...
Pα+ Psychedelic Bulletin #217:
- Gilgamesh’s GM-1020 Prints Positive Topline
- FDA Lifts Hold on GH Research’s 5-MeO-DMT IND
- Compass Details Pivotal PTSD Trial Design
- Cybin Becomes Helus
- much more...
psychedelicalpha.com/news/p%ce%b1...
The author is encouraging people to contact their Reps.
I won't share the 'Entities in Scope' here (seems to be cribbed from Psymposia's 'The Syndicate'), but you can find them here: tinawill.substack.com/p/citizen-re...
New: Ipsos/Psychedelic Alpha polling on how Americans view psychedelics.
"With psychedelic mental health therapies on the horizon, Americans are open to learning more"
www.ipsos.com/en-us/psyche...
🎥 2025 Year in Review: Future(s) & Open Questions
Watch the third and final video in our 2025 Year in Review series.
psychedelicalpha.com/news/2025-ye...
josh hardman
josh hardman
josh hardman
josh hardman
josh hardman
josh hardman
josh hardman
josh hardman
josh hardman
josh hardman
Cleveland Clinic staff psychiatrist and psychedelic trialist Brian Barnett sits down with Psychedelic Alpha’s Josh Hardman to discuss psychiatrists’ perceptions of the field, the role of ketamine in ‘...
Gilgamesh Prints Positive Topline from Phase 2a Study of NMDA Receptor Agonist for MDD • FDA Lifts Hold on GH Research’s Inhaled 5-MeO-DMT IND After More than Two Years • Cybin Rebrands to Helus…
psychedelicalpha.com
A Pα+ tool that allows you to monitor the status of psychedelics-related bills working their way through both state and federal legislatures in the U.S.
In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questions and potential futures in the psychedelics field via a narrated presentation.
psychedelicalpha.com
Ipsos research examines information pathways and attitudes regarding the use of psychedelics in mental health treatment
